Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex.

Tornheim JA, Starks AM, Rodwell TC, Gardy JL, Walker TM, Cirillo DM, Jayashankar L, Miotto P, Zignol M, Schito M.

Clin Infect Dis. 2019 Mar 18. pii: ciz219. doi: 10.1093/cid/ciz219. [Epub ahead of print]

PMID:
30883637
2.

Enabling precision medicine via standard communication of HTS provenance, analysis, and results.

Alterovitz G, Dean D, Goble C, Crusoe MR, Soiland-Reyes S, Bell A, Hayes A, Suresh A, Purkayastha A, King CH, Taylor D, Johanson E, Thompson EE, Donaldson E, Morizono H, Tsang H, Vora JK, Goecks J, Yao J, Almeida JS, Keeney J, Addepalli K, Krampis K, Smith KM, Guo L, Walderhaug M, Schito M, Ezewudo M, Guimera N, Walsh P, Kahsay R, Gottipati S, Rodwell TC, Bloom T, Lai Y, Simonyan V, Mazumder R.

PLoS Biol. 2018 Dec 31;16(12):e3000099. doi: 10.1371/journal.pbio.3000099. eCollection 2018 Dec.

3.

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

Ezewudo M, Borens A, Chiner-Oms Á, Miotto P, Chindelevitch L, Starks AM, Hanna D, Liwski R, Zignol M, Gilpin C, Niemann S, Kohl TA, Warren RM, Crook D, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, McNerney R, Cirillo DM, Schito M, Rodwell TC, Posey J.

Sci Rep. 2018 Oct 18;8(1):15382. doi: 10.1038/s41598-018-33731-1.

4.

Cost analysis of rapid diagnostics for drug-resistant tuberculosis.

Groessl EJ, Ganiats TG, Hillery N, Trollip A, Jackson RL, Catanzaro DG, Rodwell TC, Garfein RS, Rodrigues C, Crudu V, Victor TC, Catanzaro A.

BMC Infect Dis. 2018 Mar 2;18(1):102. doi: 10.1186/s12879-018-3013-0.

5.

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.

Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC.

Eur Respir J. 2017 Dec 28;50(6). pii: 1701354. doi: 10.1183/13993003.01354-2017. Print 2017 Dec.

6.

Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting.

Rice JP, Seifert M, Moser KS, Rodwell TC.

PLoS One. 2017 Oct 9;12(10):e0186139. doi: 10.1371/journal.pone.0186139. eCollection 2017.

7.

A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis.

Ramirez-Busby SM, Rodwell TC, Fink L, Catanzaro D, Jackson RL, Pettigrove M, Catanzaro A, Valafar F.

Sci Rep. 2017 Jun 19;7(1):3790. doi: 10.1038/s41598-017-03452-y.

8.

Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis.

Seifert M, Georghiou SB, Garfein RS, Catanzaro D, Rodwell TC.

Clin Infect Dis. 2017 Sep 1;65(5):772-778. doi: 10.1093/cid/cix422.

9.

Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs.

Georghiou SB, Seifert M, Catanzaro DG, Garfein RS, Rodwell TC.

J Clin Microbiol. 2017 Jun;55(6):1928-1937. doi: 10.1128/JCM.00152-17. Epub 2017 Apr 12.

10.

Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.

Catanzaro DG, Trollip AP, Seifert M, Georghiou SB, Garfein RS, Rodwell TC, Catanzaro A, Eisenach KD.

Eur Respir J. 2017 Apr 5;49(4). pii: 1602215. doi: 10.1183/13993003.02215-2016. Print 2017 Apr. No abstract available.

11.

Next-generation sequencing-based user-friendly platforms for drug-resistant tuberculosis diagnosis: A promise for the near future.

Dolinger DL, Colman RE, Engelthaler DM, Rodwell TC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S27-S28. doi: 10.1016/j.ijmyco.2016.09.021. Epub 2016 Oct 28.

12.

Mobility patterns of persons at risk for drug-resistant tuberculosis in Mumbai, India.

Conners E, Garfein RS, Rodwell TC, Udwadia ZF, Catanzaro DG.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1633-1638.

PMID:
27931339
13.

Corrigendum to "Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables" [Int. J. Mycobacteriol. 5(1) 2016 1-6].

Kambli P, Ajbani K, Nikam C, Sadani M, Shetty A, Udwadia Z, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C.

Int J Mycobacteriol. 2016 Sep;5(3):370-372. doi: 10.1016/j.ijmyco.2016.06.009. Epub 2016 Jun 27. No abstract available.

14.

Surveillance or support: The experience of direct observation during tuberculosis treatment.

Bojorquez I, Salazar I, Garfein RS, Cerecer P, Rodwell TC.

Glob Public Health. 2018 Jul;13(7):804-818. doi: 10.1080/17441692.2016.1240823. Epub 2016 Oct 16.

PMID:
27748157
15.

Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis.

Georghiou SB, Seifert M, Lin SY, Catanzaro D, Garfein RS, Jackson RL, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC.

BMC Infect Dis. 2016 Aug 31;16:458. doi: 10.1186/s12879-016-1781-y.

16.

Host Biomarkers for Distinguishing Bacterial from Non-Bacterial Causes of Acute Febrile Illness: A Comprehensive Review.

Kapasi AJ, Dittrich S, González IJ, Rodwell TC.

PLoS One. 2016 Aug 3;11(8):e0160278. doi: 10.1371/journal.pone.0160278. eCollection 2016. Review.

17.

Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study.

Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, Engelthaler DM.

J Clin Microbiol. 2016 Aug;54(8):2058-67. doi: 10.1128/JCM.00535-16. Epub 2016 May 25.

18.

Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3994-4004. doi: 10.1128/AAC.00222-16. Print 2016 Jul.

19.

A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis.

Seifert M, Ajbani K, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC.

Int J Tuberc Lung Dis. 2016 May;20(5):631-7. doi: 10.5588/ijtld.15.0788.

20.

Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.

Berrada ZL, Lin SY, Rodwell TC, Nguyen D, Schecter GF, Pham L, Janda JM, Elmaraachli W, Catanzaro A, Desmond E.

Diagn Microbiol Infect Dis. 2016 Jun;85(2):177-81. doi: 10.1016/j.diagmicrobio.2016.01.019. Epub 2016 Feb 3.

21.

Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.

Kambli P, Ajbani K, Nikam C, Sadani M, Shetty A, Udwadia Z, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C.

Int J Mycobacteriol. 2016 Mar;5(1):1-6. doi: 10.1016/j.ijmyco.2015.09.001. Epub 2015 Oct 1. Erratum in: Int J Mycobacteriol. 2016 Sep;5(3):370-372.

22.

Performance of a pyrosequencing platform in diagnosing drug-resistant extra-pulmonary tuberculosis in India.

Georghiou SB, Ajbani K, Rodrigues C, Rodwell TC.

Int J Tuberc Lung Dis. 2016 Feb;20(2):160-5. doi: 10.5588/ijtld.15.0459.

23.

Redefining MTBDRplus test results: what do indeterminate results actually mean?

Nikam C, Patel R, Sadani M, Ajbani K, Kazi M, Soman R, Shetty A, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C.

Int J Tuberc Lung Dis. 2016 Feb;20(2):154-9. doi: 10.5588/ijtld.15.0319.

24.

MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis.

Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC.

J Clin Microbiol. 2016 Apr;54(4):912-8. doi: 10.1128/JCM.02505-15. Epub 2016 Jan 13.

25.

Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations.

Kambli P, Ajbani K, Nikam C, Khillari A, Shetty A, Udwadia Z, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1227-9. doi: 10.5588/ijtld.14.0277.

26.

Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.

ElMaraachli W, Slater M, Berrada ZL, Lin SY, Catanzaro A, Desmond E, Rodrigues C, Victor TC, Crudu V, Gler MT, Rodwell TC.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1222-6. doi: 10.5588/ijtld.14.0936.

27.

Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis.

Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert M, Georghiou SB, Trollip A, Groessl E, Hillery N, Crudu V, Victor TC, Rodrigues C, Lin GS, Valafar F, Desmond E, Eisenach K.

PLoS One. 2015 Aug 31;10(8):e0136861. doi: 10.1371/journal.pone.0136861. eCollection 2015.

28.

Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study.

Garfein RS, Collins K, Muñoz F, Moser K, Cerecer-Callu P, Raab F, Rios P, Flick A, Zúñiga ML, Cuevas-Mota J, Liang K, Rangel G, Burgos JL, Rodwell TC, Patrick K.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1057-64. doi: 10.5588/ijtld.14.0923.

29.

Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.

Torres JN, Paul LV, Rodwell TC, Victor TC, Amallraja AM, Elghraoui A, Goodmanson AP, Ramirez-Busby SM, Chawla A, Zadorozhny V, Streicher EM, Sirgel FA, Catanzaro D, Rodrigues C, Gler MT, Crudu V, Catanzaro A, Valafar F.

Emerg Microbes Infect. 2015 Jul;4(7):e42. doi: 10.1038/emi.2015.42. Epub 2015 Jul 15.

30.

Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing.

Colman RE, Schupp JM, Hicks ND, Smith DE, Buchhagen JL, Valafar F, Crudu V, Romancenco E, Noroc E, Jackson L, Catanzaro DG, Rodwell TC, Catanzaro A, Keim P, Engelthaler DM.

PLoS One. 2015 May 13;10(5):e0126626. doi: 10.1371/journal.pone.0126626. eCollection 2015.

31.

Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates.

Garfein RS, Catanzaro DG, Rodwell TC, Avalos E, Jackson RL, Kaping J, Evasco H, Rodrigues C, Crudu V, Lin SY, Groessl E, Hillery N, Trollip A, Ganiats T, Victor TC, Eisenach K, Valafar F, Channick J, Qian L, Catanzaro A.

Int J Tuberc Lung Dis. 2015 Apr;19(4):420-7. doi: 10.5588/ijtld.14.0488. Erratum in: Int J Tuberc Lung Dis. 2015 Jul;19(7):874. Groessel, E [corrected to Groessl, E].

32.

Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review.

Seifert M, Catanzaro D, Catanzaro A, Rodwell TC.

PLoS One. 2015 Mar 23;10(3):e0119628. doi: 10.1371/journal.pone.0119628. eCollection 2015. Review.

33.

Defining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations.

Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C.

Diagn Microbiol Infect Dis. 2015 May;82(1):49-53. doi: 10.1016/j.diagmicrobio.2015.01.009. Epub 2015 Jan 29.

34.

Prognostic significance of novel katG mutations in Mycobacterium tuberculosis.

Valafar F, Ramirez-Busby SM, Torres J, Paul LV, Rodwell TC, Victor TC, Rodrigues C, Gler MT, Crudu V, Catanzaro T.

Int J Mycobacteriol. 2015 Mar;4(Suppl 1):51-52. Epub 2015 Jan 7.

35.

Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.

Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z, Rodwell TC, Catanzaro A, Rodrigues C.

Tuberculosis (Edinb). 2015 Mar;95(2):137-41. doi: 10.1016/j.tube.2014.11.003. Epub 2014 Dec 3.

36.

The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis.

Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein RS, Lin SY, Eisenach K, Ganiats TG, Park D, Valafar F, Rodrigues C, Crudu V, Victor TC, Catanzaro A.

Trials. 2014 Nov 6;15:434. doi: 10.1186/1745-6215-15-434.

37.

Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries.

Ajbani K, Lin SY, Rodrigues C, Nguyen D, Arroyo F, Kaping J, Jackson L, Garfein RS, Catanzaro D, Eisenach K, Victor TC, Crudu V, Gler MT, Ismail N, Desmond E, Catanzaro A, Rodwell TC.

Antimicrob Agents Chemother. 2015 Jan;59(1):414-20. doi: 10.1128/AAC.03614-14. Epub 2014 Nov 3.

38.

Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010-October 2012.

Bennett RJ, Brodine S, Waalen J, Moser K, Rodwell TC.

Am J Public Health. 2014 Apr;104(4):e95-e102. doi: 10.2105/AJPH.2013.301637. Epub 2014 Feb 13.

39.

Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens.

Lin SY, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, Desmond EP.

J Clin Microbiol. 2014 Feb;52(2):475-82. doi: 10.1128/JCM.01821-13. Epub 2013 Nov 27.

40.

Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.

Trollip AP, Moore D, Coronel J, Caviedes L, Klages S, Victor T, Romancenco E, Crudu V, Ajbani K, Vineet VP, Rodrigues C, Jackson RL, Eisenach K, Garfein RS, Rodwell TC, Desmond E, Groessl EJ, Ganiats TG, Catanzaro A.

Int J Tuberc Lung Dis. 2014 Feb;18(2):227-32. doi: 10.5588/ijtld.13.0229.

41.

Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.

Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gler MT, Catanzaro A.

J Clin Microbiol. 2014 Mar;52(3):781-9. doi: 10.1128/JCM.02701-13. Epub 2013 Dec 18.

42.

Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient's perspective.

Morris MD, Quezada L, Bhat P, Moser K, Smith J, Perez H, Laniado-Laborin R, Estrada-Guzman J, Rodwell TC.

Int J Tuberc Lung Dis. 2013 Jul;17(7):954-60. doi: 10.5588/ijtld.12.0480.

43.

Multidrug-resistant tuberculosis among patients in Baja California, Mexico, and Hispanic patients in California.

Bojorquez I, Barnes RF, Flood J, López-Gatell H, Garfein RS, Bäcker CE, Alpuche C, Vinetz JM, Catanzaro A, Kato-Maeda M, Rodwell TC.

Am J Public Health. 2013 Jul;103(7):1301-5. doi: 10.2105/AJPH.2012.301039. Epub 2013 May 16.

44.

Cigarette-Smoking Intensity and Interferon-Gamma Release Assay Conversion among Persons Who Inject Drugs: A Cohort Study.

Shin SS, Gallardo M, Lozada R, Abramovitz D, Burgos JL, Laniado-Laborin R, Rodwell TC, Novotny TE, Strathdee SA, Garfein RS.

Pulm Med. 2012;2012:828106. doi: 10.1155/2012/828106. Epub 2012 Dec 10.

45.

Factors associated with genotype clustering of Mycobacterium tuberculosis isolates in an ethnically diverse region of southern California, United States.

Rodwell TC, Kapasi AJ, Barnes RF, Moser KS.

Infect Genet Evol. 2012 Dec;12(8):1917-25. doi: 10.1016/j.meegid.2012.08.022. Epub 2012 Sep 13.

46.

Tuberculosis testing among populations with high HIV risk in Tijuana, Baja California, Mexico.

Velasquez MG, Laniado-Laborin R, Rodwell TC, Cerecer P, Lozada R, Cuevas-Mota J, Burgos JL, Garfein RS.

Rev Panam Salud Publica. 2012 Jul;32(1):30-5.

47.

HIV infection risk among injection drug users in a methadone maintenance treatment program, Taipei, Taiwan 2007-2010.

Yen YF, Rodwell TC, Yen MY, Hsu YH, Chuang P, Li LH, Su LW, Yang YH, Jiang XR, Fang YC, Garfein RS.

Am J Drug Alcohol Abuse. 2012 Nov;38(6):544-50. doi: 10.3109/00952990.2012.702171. Epub 2012 Jul 11.

48.

Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review.

Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC.

PLoS One. 2012;7(3):e33275. doi: 10.1371/journal.pone.0033275. Epub 2012 Mar 29. Review.

49.

DOT associated with reduced all-cause mortality among tuberculosis patients in Taipei, Taiwan, 2006-2008.

Yen YF, Rodwell TC, Yen MY, Shih HC, Hu BS, Li LH, Shie YH, Chuang P, Garfein RS.

Int J Tuberc Lung Dis. 2012 Feb;16(2):178-84. doi: 10.5588/ijtld.11.0034.

50.

Trends in mortality of tuberculosis patients in the United States: the long-term perspective.

Barnes RF, Moore ML, Garfein RS, Brodine S, Strathdee SA, Rodwell TC.

Ann Epidemiol. 2011 Oct;21(10):791-5. doi: 10.1016/j.annepidem.2011.07.002. Epub 2011 Aug 5.

Supplemental Content

Loading ...
Support Center